Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: Considerations on drug-drug interactions

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 3, 2011, Pages 175-184

  Choi, Min Koo ^a   Jin, Qing Ri ^b   Choi, Yeong Lim ^c   Ahn, Sung Hoon ^d   Bae, Myung Ae ^d   Song, Im Sook ^c  

^a Dankook University   (South Korea)

^b Seoul National University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Ketoconazole; OAT1; OATP1B1; Olmesartan; Rifampin; Transporter mediated drug drug interaction

Indexed keywords

KETOCONAZOLE; OLMESARTAN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG UPTAKE; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; ANTIFUNGAL AGENTS; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; IMIDAZOLES; KETOCONAZOLE; OOCYTES; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; RIFAMPIN; TETRAZOLES; XENOPUS LAEVIS;

EID: 79953676852     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.749     Document Type: Article

References (33)

1. Zhao P, Ragueneau-Majlessi I, Zhang L, et al. 2009. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 49: 351-359.
2. Lin JH. 2007. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3: 81-92. (Pubitemid 47307456)
3. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. 2000. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther 68: 637-646. (Pubitemid 32059990)
4. i values and impact of CYP3A5 expression. Drug Metab Dispos 27: 180-187.
5. Choo EF, Leake B, Wandel C, et al. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660. (Pubitemid 30390404)
6. Oo C, Chen YC. 2009. The need for multiple doses of 400mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study. J Clin Pharmacol 49: 368-369; author reply 370.
7. Takeda S, Kitajima Y, Ishii Y, et al. 2006. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34: 1277-1282. (Pubitemid 44079866)
8. Yong WP, Ramirez J, Innocenti F, Ratain MJ. 2005. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11: 6699-6704. (Pubitemid 41339012)
9. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27: 866-871. (Pubitemid 29347585)
10. Backman JT, Luurila H, NeuvonenM, Neuvonen PJ. 2005. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 78: 154-167. (Pubitemid 41112284)
11. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. 1996. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796-801. (Pubitemid 26334275)
12. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. 1999. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39: 91-96. (Pubitemid 29053157)
13. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42: 819-850. (Pubitemid 36995083)
14. Lau YY, Huang Y, Frassetto L, Benet LZ. 2007. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81: 194-204. (Pubitemid 46174816)
15. Treiber A, Schneiter R, Hausler S, Stieger B. 2007. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35: 1400-1407. (Pubitemid 47121782)
16. Sekine T, Cha SH, Tsuda M, et al. 1998. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 429: 179-182. (Pubitemid 28288205)
17. Deng JW, Song IS, Shin HJ, et al. 2008. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1* 15. Pharmacogenet Genomics 18: 424-433. (Pubitemid 351535943)
18. Shin HJ, Lee CH, Park SJ, Shin JG, Song IS. 2010. Establishment and characterization of Mardin-Darby canine kidney cells stably expressing human organic anion transporters. Arch Pharm Res 33: 709-716.
19. Liu D, Hu P, Matsushima N, Li X, Li L, Jiang J. 2007. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 856: 190-197. (Pubitemid 47302911)
20. Tirona RG, Leake BF, Wolkoff AW, Kim RB. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228. (Pubitemid 36008932)
21. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. 2002. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172. (Pubitemid 34700774)
22. Timmermans PB, Wong PC, Chiu AT, et al. 1993. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45: 205-251. (Pubitemid 23191415)
23. Wehling M. 2004. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Clin Ther 26 (Suppl A): A21-A27.
24. Destro M, Preti P, D'Ospina A, Christian Achiri NN, Ricci AR, Cagnoni F. 2009. Olmesartan medoxomil: recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol 5: 1149-1157.
25. Schwocho LR, Masonson HN. 2001. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 41: 515-527. (Pubitemid 32381869)
26. Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O. 2009. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dispos 37: 1956-1962.
27. Yamada A, Maeda K, Kamiyama E, et al. 2007. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos 35: 2166-2176. (Pubitemid 350146202)
28. Suwannakul S, Ieiri I, Kimura M, et al. 2008. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet 53: 899-904.
29. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2006. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34: 1229-1236.
30. He YJ, Zhang W, Chen Y, et al. 2009. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 405: 49-52.
31. Hartkoorn RC, Khoo S, Back DJ, et al. 2007. A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. J Chromatogr B Analyt Technol Biomed Life Sci 857: 76-82. (Pubitemid 47371222)
32. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. 1986. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 30: 206-210. (Pubitemid 16038748)
33. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM 1997. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol 20: 592-599. (Pubitemid 27509886)